Ensysce Biosciences (ENSC) Asset Utilization Ratio (2021 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Asset Utilization Ratio of 1.03 for Q3 2025, up 41.24% year-over-year from 0.73 in Q3 2024, and down 29.56% quarter-over-quarter from 1.46 in Q2 2025.
Ensysce Biosciences (ENSC) Asset Utilization Ratio (2021 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Asset Utilization Ratio for 5 consecutive years, with 1.03 the latest figure, recorded in Q3 2025.
- In Q3 2025, Asset Utilization Ratio rose 41.24% year-over-year to 1.03; the TTM figure through Sep 2025 stood at 1.03 (up 41.24% YoY), while the FY2024 annual figure was 1.25, up 141.67% from the prior year.
- Asset Utilization Ratio fell to 1.03 in Q3 2025 per ENSC's latest filing, from 1.46 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 2.16 in Q3 2021 and bottomed at 0.27 in Q1 2022.
- Historically, Asset Utilization Ratio has averaged 0.69 across 5 years, with a median of 0.55 in 2023.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio sank 84.48% — and 2025, when it surged 298.33%.
- Ensysce Biosciences' Asset Utilization Ratio stood at 0.4 in 2021, then retreated by 11.85% to 0.36 in 2022, then jumped by 111.41% to 0.75 in 2023, then declined by 7.6% to 0.7 in 2024, then jumped by 47.43% to 1.03 in 2025.
- Business Quant data shows ENSC's Asset Utilization Ratio at 1.03 in Q3 2025, 1.46 in Q2 2025, and 1.22 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.03 |
| Jun 30, 2025 | 1.46 |
| Mar 31, 2025 | 1.22 |
| Dec 31, 2024 | 0.70 |
| Sep 30, 2024 | 0.73 |
| Jun 30, 2024 | 0.37 |
| Mar 31, 2024 | 0.45 |
| Dec 31, 2023 | 0.75 |
| Sep 30, 2023 | 0.66 |
| Jun 30, 2023 | 0.58 |
| Mar 31, 2023 | 0.55 |
| Dec 31, 2022 | 0.36 |
| Sep 30, 2022 | 0.34 |
| Jun 30, 2022 | 0.36 |
| Mar 31, 2022 | 0.27 |
| Dec 31, 2021 | 0.40 |
| Sep 30, 2021 | 2.16 |
| Jun 30, 2021 | 0.28 |
| Mar 31, 2021 | 0.50 |